Simulations Plus Inc Dossier
Qualitative Analysis
Business overview
Simulations Plus, Inc. is a premier developer of model-informed and AI-accelerated drug development software and scientific consulting services for the pharmaceutical and biotechnology industries. The company's advanced software platforms, including GastroPlus, ADMET Predictor, MonolixSuite, and quantitative systems pharmacology/toxicology (QSP/QST) tools, enable researchers to predict key molecular endpoints, absorption, and pharmacokinetics in silico. This significantly reduces research and development costs and accelerates clinical decision-making. Simulations Plus operates through two primary segments: Software, which generates high-margin recurring subscription revenue, and Services, which provides specialized clinical pharmacology and mechanistic modeling consulting.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle, applying AI within scientifically grounded modeling workflows.
Expected impact: Enables natural language interaction, automation of data processing, and coordination of simulations across multiple modeling engines (GastroPlus, MonolixSuite, ADMET Predictor, Thales).
Transitioning from a portfolio of standalone best-in-class tools into an orchestrated, unified cloud-enabled ecosystem spanning discovery, development, clinical operations, and commercialization.
Expected impact: Improves client productivity, provides richer data insights, and streamlines decision support with regulator-ready documentation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of predictive computer models based on biological responses to diseases and drug interventions to expand quantitative systems pharmacology (QSP) capabilities.
Financial impact: Contributed to the expansion of the services segment and overall biosimulation portfolio.
Strategic Partnerships
High. These programs apply AI within scientifically grounded modeling workflows to define how next-generation workflows are deployed at scale.
Terms: Not publicly disclosed.